• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.78
  • 0.68 %
  • $257.68
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
LumiraDx Limited (LMDX) Stock Price, News & Analysis

LumiraDx Limited (LMDX) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.02
Day's range
$0.03
50-day range
$0.0075
Day's range
$0.3059
  • Country: GB
  • ISIN: KYG5709L1095
52 wk range
$0.02
Day's range
$0.03
  • CEO: Ms. Veronique Ameye EMBA, Esq., M.B.A.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -6.65
  • Piotroski Score 1.00
  • Grade Outperform
  • Symbol (LMDX)
  • Company LumiraDx Limited
  • Price $0.02
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $0.02
  • Day High $0.03
  • Year High $0.03

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 05/14/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $1.50
  • High Stock Price Target $1.50
  • Low Stock Price Target $1.50
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.08
  • Trailing P/E Ratio -0.01
  • Forward P/E Ratio -0.01
  • P/E Growth -0.01
  • Net Income $-449,195,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

LumiraDx Limited Frequently Asked Questions

  • What is the LumiraDx Limited stock price today?

    Today's price of LumiraDx Limited is $0.02 — it has decreased by 0% in the past 24 hours. Watch LumiraDx Limited stock price performance more closely on the chart.

  • Does LumiraDx Limited release reports?

    Yes, you can track LumiraDx Limited's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the LumiraDx Limited stock forecast?

    Watch the LumiraDx Limited chart and read a more detailed LumiraDx Limited stock forecast to see what analysts suggest you do with its shares.

  • What is LumiraDx Limited stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by LumiraDx Limited stock ticker.

  • How to buy LumiraDx Limited stocks?

    Like other stocks, LMDX shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is LumiraDx Limited's EBITDA?

    LumiraDx Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in LumiraDx Limited’s financial statements.

  • What is the LumiraDx Limited's net income ratio for the financial year 2022?

    The net income ratio for the financial year 2022 is -1.7651762838, which equates to approximately -176.52%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in LumiraDx Limited stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including LumiraDx Limited's financials relevant news, and technical analysis. LumiraDx Limited's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for LumiraDx Limited stock currently indicates a “sell” signal. For more insights, review LumiraDx Limited’s technical analysis.

  • A revenue figure for LumiraDx Limited for its last quarter?

    LumiraDx Limited published it's last quarterly revenues at $21.00 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.